Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Pancreatic Cancer-Pipeline Review, H1 2015

Metastatic Pancreatic Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Pancreatic Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Pancreatic Cancer-Pipeline Review, H1 2015', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Metastatic Pancreatic Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Metastatic Pancreatic Cancer-Overview 10

Pipeline Products for Metastatic Pancreatic Cancer-Comparative Analysis 11

Metastatic Pancreatic Cancer-Therapeutics under Development by Companies 12

Metastatic Pancreatic Cancer-Therapeutics under Investigation by Universities/Institutes 17

Metastatic Pancreatic Cancer-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Metastatic Pancreatic Cancer-Products under Development by Companies 21

Metastatic Pancreatic Cancer-Products under Investigation by Universities/Institutes 26

Metastatic Pancreatic Cancer-Companies Involved in Therapeutics Development 27

AbbVie Inc. 27

Aduro BioTech, Inc. 28

AstraZeneca PLC 29

AVEO Pharmaceuticals, Inc. 30

Axcentua Pharmaceuticals AB 31

Bayer AG 32

BioCancell Therapeutics, Inc. 33

Boehringer Ingelheim GmbH 34

Boston Biomedical, Inc. 35

Cantex Pharmaceuticals, Inc. 36

Celgene Corporation 37

Colby Pharmaceutical Company 38

Cornerstone Pharmaceuticals, Inc. 39

Eleison Pharmaceuticals, Inc. 40

Eli Lilly and Company 41

F. Hoffmann-La Roche Ltd. 42

FibroGen, Inc. 43

Fountain Biopharma Inc. 44

Gilead Sciences, Inc. 45

GlaxoSmithKline plc 46

Halozyme Therapeutics, Inc. 47

Immunomedics, Inc. 48

Incyte Corporation 49

Merck & Co., Inc. 50

Merck KGaA 51

Merrimack Pharmaceuticals, Inc. 52

Momenta Pharmaceuticals, Inc. 53

NanoCarrier Co., Ltd. 54

Nanotherapeutics, Inc. 55

NewLink Genetics Corporation 56

Novartis AG 57

Oncolytics Biotech Inc. 58

OncoMed Pharmaceuticals, Inc. 59

Oncovir, Inc. 60

Oncozyme Pharma Inc. 61

Pfizer Inc. 62

Pharma Mar, S.A. 63

Precision Biologics, Inc. 64

Regulon Inc. 65

Rexahn Pharmaceuticals, Inc. 66

Sanofi 67

Silence Therapeutics plc 68

Synta Pharmaceuticals Corp. 69

Takeda Oncology 70

Teva Pharmaceutical Industries Limited 71

Threshold Pharmaceuticals, Inc. 72

Metastatic Pancreatic Cancer-Therapeutics Assessment 73

Assessment by Monotherapy Products 73

Assessment by Combination Products 74

Assessment by Target 75

Assessment by Mechanism of Action 78

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

Atu-027-Drug Profile 85

AXP-10711-Drug Profile 87

BBI-608-Drug Profile 89

BC-819-Drug Profile 91

bevacizumab-Drug Profile 93

BI-853520-Drug Profile 98

binimetinib-Drug Profile 100

CEP-37250-Drug Profile 104

CIM-1-Drug Profile 105

cisplatin-Drug Profile 106

cisplatin liposomal-Drug Profile 108

clivatuzumab tetraxetan-Drug Profile 110

CPC-410-Drug Profile 112

CPI-613-Drug Profile 113

CRS-207-Drug Profile 115

demcizumab-Drug Profile 117

Dendritic Cell Therapy for Cancer-Drug Profile 121

ensituximab-Drug Profile 122

erismodegib-Drug Profile 124

evofosfamide-Drug Profile 127

FB-704A-Drug Profile 134

FG-3019-Drug Profile 135

ficlatuzumab-Drug Profile 137

galunisertib-Drug Profile 140

ganetespib-Drug Profile 142

glufosfamide-Drug Profile 146

indoximod-Drug Profile 148

irinotecan sucrosofate liposomal-Drug Profile 150

lapatinib ditosylate-Drug Profile 153

LCL-161-Drug Profile 157

LGK-974-Drug Profile 159

lurbinectedin-Drug Profile 160

LY-2109761-Drug Profile 162

LY-2495655-Drug Profile 163

MesoCART-Drug Profile 164

MK-2206-Drug Profile 165

MK-2206 + selumetinib sulfate-Drug Profile 168

MLN-0264-Drug Profile 170

necuparanib-Drug Profile 171

nimotuzumab-Drug Profile 172

olaparib-Drug Profile 175

paclitaxel albumin bound-Drug Profile 179

paclitaxel lipsomal-Drug Profile 183

PD-0325901 + PF-05212384-Drug Profile 185

PEGPH-20-Drug Profile 186

pelareorep-Drug Profile 187

pentamidine isethionate-Drug Profile 192

PGX-100-Drug Profile 194

pimasertib hydrochloride-Drug Profile 196

plerixafor-Drug Profile 198

Poly-ICLC-Drug Profile 200

PRI-724-Drug Profile 202

refametinib-Drug Profile 204

rottlerin-Drug Profile 207

ruxolitinib phosphate-Drug Profile 208

RX-0201-Drug Profile 213

SGT-53-Drug Profile 215

SiG12D-LODER-Drug Profile 216

simtuzumab-Drug Profile 218

Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer-Drug Profile 220

Stem Cell Therapy for Oncology-Drug Profile 221

TL-118-Drug Profile 222

trametinib dimethyl sulfoxide-Drug Profile 224

Triapine-Drug Profile 227

Vaccine to Target VEGFR-1 and VEGFR-2 for Metastatic Hepatocellular Carcinoma and Metastatic Pancreatic Cancer-Drug Profile 229

veliparib-Drug Profile 230

Metastatic Pancreatic Cancer-Recent Pipeline Updates 233

Metastatic Pancreatic Cancer-Dormant Projects 334

Metastatic Pancreatic Cancer-Discontinued Products 337

Metastatic Pancreatic Cancer-Product Development Milestones 339

Featured News & Press Releases 339

Appendix 348

Methodology 348

Coverage 348

Secondary Research 348

Primary Research 348

Expert Panel Validation 348

Contact Us 349

Disclaimer 349

List of Tables

Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015 15

Number of Products under Development for Metastatic Pancreatic Cancer-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Products under Development by Companies, H1 2015 26

Products under Development by Companies, H1 2015 (Contd..1) 27

Products under Development by Companies, H1 2015 (Contd..2) 28

Products under Development by Companies, H1 2015 (Contd..3) 29

Products under Development by Companies, H1 2015 (Contd..4) 30

Products under Investigation by Universities/Institutes, H1 2015 31

Metastatic Pancreatic Cancer-Pipeline by AbbVie Inc., H1 2015 32

Metastatic Pancreatic Cancer-Pipeline by Aduro BioTech, Inc., H1 2015 33

Metastatic Pancreatic Cancer-Pipeline by AstraZeneca PLC, H1 2015 34

Metastatic Pancreatic Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 35

Metastatic Pancreatic Cancer-Pipeline by Axcentua Pharmaceuticals AB, H1 2015 36

Metastatic Pancreatic Cancer-Pipeline by Bayer AG, H1 2015 37

Metastatic Pancreatic Cancer-Pipeline by BioCancell Therapeutics, Inc., H1 2015 38

Metastatic Pancreatic Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 39

Metastatic Pancreatic Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 40

Metastatic Pancreatic Cancer-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 41

Metastatic Pancreatic Cancer-Pipeline by Celgene Corporation, H1 2015 42

Metastatic Pancreatic Cancer-Pipeline by Colby Pharmaceutical Company, H1 2015 43

Metastatic Pancreatic Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 44

Metastatic Pancreatic Cancer-Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 45

Metastatic Pancreatic Cancer-Pipeline by Eli Lilly and Company, H1 2015 46

Metastatic Pancreatic Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 47

Metastatic Pancreatic Cancer-Pipeline by FibroGen, Inc., H1 2015 48

Metastatic Pancreatic Cancer-Pipeline by Fountain Biopharma Inc., H1 2015 49

Metastatic Pancreatic Cancer-Pipeline by Gilead Sciences, Inc., H1 2015 50

Metastatic Pancreatic Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 51

Metastatic Pancreatic Cancer-Pipeline by Halozyme Therapeutics, Inc., H1 2015 52

Metastatic Pancreatic Cancer-Pipeline by Immunomedics, Inc., H1 2015 53

Metastatic Pancreatic Cancer-Pipeline by Incyte Corporation, H1 2015 54

Metastatic Pancreatic Cancer-Pipeline by Merck & Co., Inc., H1 2015 55

Metastatic Pancreatic Cancer-Pipeline by Merck KGaA, H1 2015 56

Metastatic Pancreatic Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 57

Metastatic Pancreatic Cancer-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 58

Metastatic Pancreatic Cancer-Pipeline by NanoCarrier Co., Ltd., H1 2015 59

Metastatic Pancreatic Cancer-Pipeline by Nanotherapeutics, Inc., H1 2015 60

Metastatic Pancreatic Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 61

Metastatic Pancreatic Cancer-Pipeline by Novartis AG, H1 2015 62

Metastatic Pancreatic Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 63

Metastatic Pancreatic Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 64

Metastatic Pancreatic Cancer-Pipeline by Oncovir, Inc., H1 2015 65

Metastatic Pancreatic Cancer-Pipeline by Oncozyme Pharma Inc., H1 2015 66

Metastatic Pancreatic Cancer-Pipeline by Pfizer Inc., H1 2015 67

Metastatic Pancreatic Cancer-Pipeline by Pharma Mar, S.A., H1 2015 68

Metastatic Pancreatic Cancer-Pipeline by Precision Biologics, Inc., H1 2015 69

Metastatic Pancreatic Cancer-Pipeline by Regulon Inc., H1 2015 70

Metastatic Pancreatic Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 71

Metastatic Pancreatic Cancer-Pipeline by Sanofi, H1 2015 72

Metastatic Pancreatic Cancer-Pipeline by Silence Therapeutics plc, H1 2015 73

Metastatic Pancreatic Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 74

Metastatic Pancreatic Cancer-Pipeline by Takeda Oncology, H1 2015 75

Metastatic Pancreatic Cancer-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76

Metastatic Pancreatic Cancer-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 77

Assessment by Monotherapy Products, H1 2015 78

Assessment by Combination Products, H1 2015 79

Number of Products by Stage and Target, H1 2015 81

Number of Products by Stage and Mechanism of Action, H1 2015 84

Number of Products by Stage and Route of Administration, H1 2015 87

Number of Products by Stage and Molecule Type, H1 2015 89

Metastatic Pancreatic Cancer Therapeutics-Recent Pipeline Updates, H1 2015 238

Metastatic Pancreatic Cancer-Dormant Projects, H1 2015 339

Metastatic Pancreatic Cancer-Dormant Projects (Contd..1), H1 2015 340

Metastatic Pancreatic Cancer-Dormant Projects (Contd..2), H1 2015 341

Metastatic Pancreatic Cancer-Discontinued Products, H1 2015 342

Metastatic Pancreatic Cancer-Discontinued Products (Contd..1), H1 2015 343

List of Figures

Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015 15

Number of Products under Development for Metastatic Pancreatic Cancer-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 78

Assessment by Combination Products, H1 2015 79

Number of Products by Stage and Top 10 Targets, H1 2015 80

Number of Products by Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Top 10 Routes of Administration, H1 2015 86

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86

Number of Products by Top 10 Molecule Types, H1 2015 88

Number of Products by Stage and Top 10 Molecule Types, H1 2015 88

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Aduro BioTech, Inc.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Axcentua Pharmaceuticals AB

Bayer AG

BioCancell Therapeutics, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Cantex Pharmaceuticals, Inc.

Celgene Corporation

Colby Pharmaceutical Company

Cornerstone Pharmaceuticals, Inc.

Eleison Pharmaceuticals, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Fountain Biopharma Inc.

Gilead Sciences, Inc.

GlaxoSmithKline plc

Halozyme Therapeutics, Inc.

Immunomedics, Inc.

Incyte Corporation

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.

NanoCarrier Co., Ltd.

Nanotherapeutics, Inc.

NewLink Genetics Corporation

Novartis AG

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Oncovir, Inc.

Oncozyme Pharma Inc.

Pfizer Inc.

Pharma Mar, S.A.

Precision Biologics, Inc.

Regulon Inc.

Rexahn Pharmaceuticals, Inc.

Sanofi

Silence Therapeutics plc

Synta Pharmaceuticals Corp.

Takeda Oncology

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

Metastatic Pancreatic Cancer Therapeutic Products under Development, Key Players in Metastatic Pancreatic Cancer Therapeutics, Metastatic Pancreatic Cancer Pipeline Overview, Metastatic Pancreatic Cancer Pipeline, Metastatic Pancreatic Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com